CN1853625A - 木犀草素与一种铂类化疗药物的联合 - Google Patents
木犀草素与一种铂类化疗药物的联合 Download PDFInfo
- Publication number
- CN1853625A CN1853625A CN 200610074209 CN200610074209A CN1853625A CN 1853625 A CN1853625 A CN 1853625A CN 200610074209 CN200610074209 CN 200610074209 CN 200610074209 A CN200610074209 A CN 200610074209A CN 1853625 A CN1853625 A CN 1853625A
- Authority
- CN
- China
- Prior art keywords
- sweet
- scented osmanthus
- luteolin
- platinum
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 235000019082 Osmanthus Nutrition 0.000 title description 177
- 241000333181 Osmanthus Species 0.000 title description 177
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 235000009498 luteolin Nutrition 0.000 claims abstract description 110
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 102
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims abstract description 102
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims abstract description 102
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 79
- 229960004316 cisplatin Drugs 0.000 claims abstract description 69
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 67
- 229960004562 carboplatin Drugs 0.000 claims abstract description 56
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 39
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 37
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 57
- 239000000890 drug combination Substances 0.000 claims description 43
- 229940079593 drug Drugs 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- 238000011518 platinum-based chemotherapy Methods 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 115
- 229910052697 platinum Inorganic materials 0.000 description 57
- 230000000694 effects Effects 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 33
- 238000012360 testing method Methods 0.000 description 29
- 230000000259 anti-tumor effect Effects 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- 239000000203 mixture Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 230000002195 synergetic effect Effects 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 11
- 230000001629 suppression Effects 0.000 description 11
- -1 flavone compound Chemical class 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000008485 antagonism Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000012930 cell culture fluid Substances 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000012531 culture fluid Substances 0.000 description 7
- 238000007405 data analysis Methods 0.000 description 7
- 238000004043 dyeing Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 125000003831 tetrazolyl group Chemical group 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 201000005296 lung carcinoma Diseases 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 230000008121 plant development Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 201000011061 large intestine cancer Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WYTRYIUQUDTGSX-UHFFFAOYSA-N 1-phenylpropan-2-ol Chemical compound CC(O)CC1=CC=CC=C1 WYTRYIUQUDTGSX-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010018404 Glucagonoma Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007750 drug combination effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229950007221 nedaplatin Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀1 | 15±2.2 | ||
木犀2 | 27.75±3 | ||
木犀4 | 50.7±3 | ||
木犀8 | 72.5±3.2 | ||
木犀16 | 87.2±3.1 | ||
Pt1 | 15.2±2 | ||
Pt2 | 32.8±3 |
Pt4 | 40.9±3.5 | ||
Pt8 | 72.9±3 | ||
Pt1+木犀1 | 31.9±2.3 | 0.9 | |
Pt2+木犀2 | 55±2 | 0.85 | |
Pt4+木犀4 | 95±2 | 0.2 | |
Pt8+木犀8 | 99±3.5 | 0.11 | |
Pt1+木犀2 | 47.9±2 | 0.8 | |
Pt2+木犀4 | 75.75±3 | 0.63 | |
Pt4+木犀8 | 99±3.7 | 0.1 | |
Pt1+木犀4 | 70.82±3.2 | 0.65 | |
Pt2+木犀8 | 92±3.5 | 0.3979 | |
Pt4+木犀16 | 99±2.9 | 0.155 | |
Pt8+木犀32 | 99±3.8 | 0.311 | |
Pt1+木犀10 | 92±3 | 0.447 | |
Pt2+木犀20 | 99±2 | 0.177 | |
Pt4+木犀40 | 99±3 | 0.36 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 4.01±3 | ||
木犀5 | 10.01±3.2 | ||
木犀10 | 28.03±4.1 | ||
木犀20 | 49.37±3.7 | ||
木犀40 | 68.67±3 | ||
Pt1 | 0.01±2 | ||
Pt2 | 29.8±3.2 | ||
Pt4 | 32.85±3.7 | ||
Pt8 | 44.1±2.9 | ||
Pt1+木犀2.5 | 23.53±3.5 | 0.55 | |
Pt2+木犀5 | 64.22±3.2 | 0.38 | |
Pt4+木犀10 | 73.11±2.7 | 0.5957 | |
Pt8+木犀20 | 88.5±4.1 | 0.6475 | |
Pt1+木犀5 | 37.33±3.2 | 0.534 | |
Pt2+木犀10 | 75±3.2 | 0.48 | |
Pt4+木犀20 | 77.7±3.9 | 0.7126 | |
Pt8+木犀40 | 90.7±2.5 | 0.7584 | |
Pt1+木犀10 | 62.7±2.9 | 0.4429 | |
Pt2+木犀20 | 70±3 | 0.7168 | |
Pt4+木犀40 | 85±2.7 | 0.81 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 0.34±2 | ||
木犀5 | 0.9±2 | ||
木犀10 | 46.2±3.2 | ||
木犀20 | 67.22±2.7 | ||
木犀40 | 80.88±3.2 | ||
Pt1 | 16.32±3.5 | ||
Pt2 | 18.83±3.7 | ||
Pt4 | 38.01±3.5 | ||
Pt8 | 61.51±4.2 | ||
Pt1+木犀2.5 | 15.92±3 | 1.087 | |
Pt2+木犀5 | 21.84±3.2 | 1.56 | |
Pt4+木犀10 | 56.6±2 | 1.02 | |
Pt8+木犀20 | 87.3±3.7 | 0.778 | |
Pt1+木犀5 | 27±3.8 | 0.829 | |
Pt2+木犀10 | 53.9±3 | 0.816 | |
Pt4+木犀20 | 75.1±2 | 0.98 | |
Pt8+木犀40 | 93.52±2 | 0.9672 | |
Pt1+木犀10 | 60.33±3.2 | 0.479 |
Pt2+木犀20 | 73.04±2.3 | 0.91 | |
Pt4+木犀40 | 93±3.3 | 0.95 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 8±2 | ||
木犀5 | 19.1±3 | ||
木犀10 | 37.7±3 | ||
木犀20 | 49±3.2 | ||
木犀40 | 56.85±3.5 | ||
Pt1 | 15±3.8 | ||
Pt2 | 30.1±3 | ||
Pt4 | 48.3±4.2 | ||
Pt8 | 70.85±3.8 | ||
Pt1+木犀2.5 | 10.85±2.3 | 2.255 | |
Pt2+木犀5 | 48.1±3.5 | 0.76 |
Pt4+木犀10 | 75.1±2.5 | 0.55 | |
Pt8+木犀20 | 92.8±2.9 | 0.32 | |
Pt1+木犀5 | 39.2±2.8 | 0.689 | |
Pt2+木犀10 | 63±3 | 0.575 | |
Pt4+木犀20 | 79.6±2 | 0.55 | |
Pt8+木犀40 | 89.2±2.5 | 0.568 | |
Pt1+木犀10 | 61±3 | 0.447 | |
Pt2+木犀20 | 74.11±2.9 | 0.51 | |
Pt4+木犀40 | 88±2 | 0.429 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 7.4±2 |
木犀5 | 17.8±3 | ||
木犀10 | 45±4.2 | ||
木犀20 | 67.75±3.2 | ||
木犀40 | 79.22±2.8 | ||
Pt1 | 15.2±3 | ||
Pt2 | 30.37±2.7 | ||
Pt4 | 45.8±3 | ||
Pt8 | 72.1±3 | ||
Pt1+木犀2.5 | 22.5±2.5 | 1.1 | |
Pt2+木犀5 | 64.8±2.7 | 0.5472 | |
Pt4+木犀10 | 73.02±3.2 | 0.82 | |
Pt8+木犀20 | 92.1±2 | 0.5477 | |
Pt1+木犀5 | 49.15±2 | 0.6325 | |
Pt2+木犀10 | 76.7±3 | 0.515 | |
Pt4+木犀20 | 86.2±3.2 | 0.6446 | |
Pt8+木犀40 | 92.1±2.9 | 0.81 | |
Pt1+木犀10 | 72.25±3.5 | 0.497 | |
Pt2+木犀20 | 81.86±3.7 | 0.669 | |
Pt4+木犀40 | 95±2 | 0.4786 |
分组 | 剂量mg/kg | 给药日程 | 体重减少率% | 瘤重(g)均值±SD | 抑瘤率% | 动物数(只)始/末 |
对照组顺铂木犀木犀木犀顺铂+木犀顺铂+木犀顺铂+木犀 | -2510202+52+102+20 | 2-4,8-102-4,8-102-4,8-102-4,8-102-4,8-102-4,8-102-4,8-10 | <0<5<5<5<5<5<5<5 | 2.65±0.221.59±0.282.535±0.222.328±0.152.035±0.101.33±0.071.27±0.091.118±0.119 | 404.312.1523.249.8*##52**##57.8**# | 10/1010/1010/1010/1010/1010/1010/1010/10 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 7±2.7 | ||
木犀5 | 18±3 | ||
木犀10 | 38.7±4.1 | ||
木犀20 | 57±3.5 | ||
木犀40 | 67±2.7 | ||
奥铂1 | 32.2±3.2 | ||
奥铂2 | 49.7±2.9 | ||
奥铂4 | 59.8±3.2 | ||
奥铂8 | 67±3.2 | ||
奥铂1+木犀5 | 42±2.2 | 1 | |
奥铂2+木犀10 | 67.7±2.9 | 0.574 |
奥铂4+木犀20 | 82.2±3.5 | 0.487 | |
奥铂8+木犀40 | 92±2 | 0.387 | |
奥铂0.5+木犀5 | 39±2 | 0.785 | |
奥铂1+木犀10 | 57±3 | 0.705 | |
奥铂2+木犀20 | 79.8±3.2 | 0.465 | |
奥铂4+木犀40 | 90.2±2.9 | 0.418 | |
奥铂0.5+木犀7.5 | 45.2±3.2 | 0.753 | |
奥铂1+木犀15 | 75.8±3.2 | 0.4 | |
奥铂2+木犀30 | 92.8±2.8 | 0.221 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 4.01±3 | ||
木犀5 | 10.01±3.2 | ||
木犀10 | 28.03±4.1 | ||
木犀20 | 49.37±3.5 | ||
木犀40 | 68.67±2.7 | ||
奥铂1 | 27.8±3.1 | ||
奥铂2 | 39±3.9 | ||
奥铂4 | 50.2±3.5 | ||
奥铂8 | 79±3.2 | ||
奥铂0.5+木犀2.5 | 15±3.2 | 1.288 | |
奥铂1+木犀5 | 32±3.9 | 1.1 | |
奥铂2+木犀10 | 62±3.2 | 0.77 | |
奥铂4+木犀20 | 87±2.9 | 0.481 | |
奥铂0.5+木犀5 | 17±2.8 | 1.478 | |
奥铂1+木犀10 | 42±3.2 | 1 |
奥铂2+木犀20 | 77±3.2 | 0.627 | |
奥铂4+木犀40 | 95±2.9 | 0.332 | |
奥铂0.5+木犀7.5 | 47±3.5 | 0.575 | |
奥铂1+木犀15 | 72±3.2 | 0.5 | |
奥铂2+木犀30 | 92.9±2.9 | 0.3 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 5±3.2 | ||
木犀5 | 12.5±3.1 | ||
木犀10 | 46.2±3.5 | ||
木犀20 | 67.22±3.2 | ||
木犀40 | 80.88±2.9 | ||
奥铂1 | 30±3.2 | ||
奥铂2 | 45±3.5 | ||
奥铂4 | 52±3.5 | ||
奥铂8 | 69±3.5 | ||
奥铂0.5+木犀2.5 | 18±3.5 | 1.7 | |
奥铂1+木犀5 | 39±3.5 | 1 | |
奥铂2+木犀10 | 69±3.7 | 0.665 | |
奥铂4+木犀20 | 92±2.9 | 0.373 | |
奥铂0.5+木犀5 | 20.5±2.9 | 1.8 | |
奥铂1+木犀10 | 51±3.5 | 1 | |
奥铂2+木犀20 | 82±3.5 | 0.652 | |
奥铂4+木犀40 | 95±3.2 | 0.5 | |
奥铂0.5+木犀7.5 | 45±3.2 | 0.815 | |
奥铂1+木犀15 | 72±3.5 | 0.692 |
奥铂2+木犀30 | 92.8±2.8 | 0.472 |
分组 | 剂量mg/kg | 给药日程 | 体重减少率% | 瘤重(g)均值±SD | 抑瘤率% | 动物数(只)始/末 |
对照组奥铂木犀木犀木犀奥铂+木犀奥铂+木犀 | -21020302+102+20 | 2-4,8-102-4,8-102-4,8-102-4,8-102-4,8-102-4,8-10 | <0<5<5<5<5<5<5 | 2.65±0.221.62±0.252.328±0.152.035±0.101.58±0.051.32±0.081.219±0.06 | 38.912.1523.24048**#54**# | 10/1010/1010/1010/1010/1010/1010/10 |
奥铂+木犀 | 2+30 | 2-4,8-10 | <5 | 1.115±0.116 | 58**# | 10/10 |
单剂药物作用浓度(μm) | 联合药物作用浓度(μm) | 细胞生长抑制率(%) | 联合用药系数值(CI) |
木犀2.5 | 1±3.5 |
木犀5 | 9±3.2 | ||
木犀10 | 22±3.2 | ||
木犀20 | 49±3.8 | ||
木犀40 | 77±2.7 | ||
卡铂2.5 | 5±3.2 | ||
卡铂5 | 12±3.2 | ||
卡铂10 | 25±3.2 | ||
卡铂20 | 52±3.2 | ||
卡铂40 | 87±3.5 | ||
卡铂2.5+木犀2.5 | 7±3.2 | 1.16 | |
卡铂5+木犀5 | 32±3.2 | 0.8 | |
卡铂10+木犀10 | 59±3.9 | 0.915 | |
卡铂20+木犀20 | 87±2.7 | 0.97 | |
卡铂2.5+木犀5 | 12±2.7 | 1.17 | |
卡铂5+木犀10 | 42±2.7 | 0.96 | |
卡铂10+木犀20 | 72±3.5 | 1 | |
卡铂20+木犀40 | 92±3.2 | 0.88 | |
卡铂5+木犀2.5 | 17±3.2 | 1 | |
卡铂10+木犀5 | 59±3.2 | 0.7 | |
卡铂20+木犀10 | 82±3.2 | 0.82 | |
卡铂40+木犀20 | 92±2.8 | 0.88 |
分组 | 剂量mg/kg | 给药日程 | 体重减少率% | 瘤重(g)均值±SD | 抑瘤率% | 动物数(只)始/末 |
对照组卡铂木犀木犀木犀卡铂+木犀卡铂+木犀卡铂+木犀 | -7510207+57+107+20 | 2-4,8-102-4,8-102-4,8-102-4,8-102-4,8-102-4,8-102-4,8-10 | <0<5<5<5<5<5<5<5 | 2.65±0.221.65±0.252.535±0.222.328±0.152.035±0.101.35±0.071.23±0.071.018±0.126 | 37.74.312.1523.249**##53.58**##61.58**## | 10/1010/1010/1010/1010/1010/1010/1010/10 |
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100742098A CN100443081C (zh) | 2005-04-05 | 2006-03-30 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510024881.1 | 2005-04-05 | ||
CN200510024881 | 2005-04-05 | ||
CNB2006100742098A CN100443081C (zh) | 2005-04-05 | 2006-03-30 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1853625A true CN1853625A (zh) | 2006-11-01 |
CN100443081C CN100443081C (zh) | 2008-12-17 |
Family
ID=37194284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100742098A Expired - Fee Related CN100443081C (zh) | 2005-04-05 | 2006-03-30 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100443081C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102697768A (zh) * | 2012-06-07 | 2012-10-03 | 中国人民解放军第二军医大学 | 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途 |
CN101456881B (zh) * | 2007-12-13 | 2012-10-17 | 北京嘉事联博医药科技有限公司 | 木犀草素及其衍生物的铂类配合物、制备方法及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
AP2001002109A0 (en) * | 1998-09-25 | 2001-03-31 | Warner Lambert Co | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin. |
US7326734B2 (en) * | 2003-04-01 | 2008-02-05 | The Regents Of The University Of California | Treatment of bladder and urinary tract cancers |
-
2006
- 2006-03-30 CN CNB2006100742098A patent/CN100443081C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101456881B (zh) * | 2007-12-13 | 2012-10-17 | 北京嘉事联博医药科技有限公司 | 木犀草素及其衍生物的铂类配合物、制备方法及其应用 |
CN102697768A (zh) * | 2012-06-07 | 2012-10-03 | 中国人民解放军第二军医大学 | 一类木犀草素类似黄酮类化合物在制备抗肿瘤药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN100443081C (zh) | 2008-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103282037B (zh) | 抗肿瘤生物碱的联合治疗 | |
CN115487187B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
CN1486193A (zh) | 有效的抗肿瘤治疗方法 | |
CN102552908B (zh) | 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
CN101903028B (zh) | 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯 | |
CN1872049A (zh) | 野黄芩甙元与一种铂类化疗药物的联合 | |
CN1897949A (zh) | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 | |
CN1839865A (zh) | 抗肿瘤的黄芩甙元和黄芩甙协同药物组合物 | |
CN1853625A (zh) | 木犀草素与一种铂类化疗药物的联合 | |
CN1679539A (zh) | 抗肿瘤的协同药物组合物 | |
CN102688493A (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 | |
CN101229175A (zh) | 一对原人参二醇衍生物和它们混合体的医药用途 | |
CN1915232A (zh) | 黄岑甙元与一种铂类化疗药物的联合 | |
CN1691943A (zh) | 利用g6976及其相关化合物进行肿瘤治疗 | |
CN102688489A (zh) | 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
CN1361693A (zh) | 1,4-苯并硫氮杂∴衍生物作为抗癌药抗性克服用药物的用途 | |
CN1875958A (zh) | 协同抗肿瘤的野黄芩甙元和黄芩甙药物组合物 | |
CN1679604A (zh) | 抗肿瘤的协同药物组合物 | |
CN1879615A (zh) | 抗肿瘤的协同药物组合物 | |
CN1867573A (zh) | 制备反式-或顺式-二铵二氯二羟合铂(ⅳ)的方法及其用于制备药物有效物质的用途 | |
CN102440987B (zh) | 含有芹菜素及芹菜素类衍生物和青蒿素及青蒿素类衍生物的药物组合物及其应用 | |
CN113786491A (zh) | 一种含汉防己甲素、二氢槲皮素或槲皮素的抗肿瘤联用制剂 | |
CN106562976A (zh) | 聚普瑞锌在制备治疗结肠癌药物中的应用 | |
CN1867344A (zh) | 含有氧代铂、其盐和衍生物的药物组合物 | |
CN113893256A (zh) | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI GELU AOLI BIO-MEDICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: WU YIXIN Effective date: 20090410 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090410 Address after: Room 1, building 1225, No. 216 Shangcheng Road, Shanghai, Pudong New Area Patentee after: Shanghai Geluoli Biology Medicine Technology Co., Ltd. Address before: Room 2, No. 700, Lane 1802, Wuyi Road, Shanghai, Changning District Patentee before: Wu Yixin |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081217 Termination date: 20140330 |